TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors
Public ClinicalTrials.gov record NCT02650635. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase IB Study Investigating the Tolerability, Immunomodulatory Impacts and, Therapeutic Correlates of the Novel Toll-like Receptor 8 Agonist Motolimod (MOTO) Plus Cyclophosphamide (CTX) Treatment of Advanced Solid Tumors
Study identification
- NCT ID
- NCT02650635
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Mayo Clinic
- Other
- Enrollment
- 4 participants
Conditions and interventions
Conditions
- Colorectal Adenocarcinoma
- Metastatic Pancreatic Adenocarcinoma
- Recurrent Breast Carcinoma
- Recurrent Colorectal Carcinoma
- Recurrent Melanoma of the Skin
- Recurrent Non-Small Cell Lung Carcinoma
- Recurrent Pancreatic Carcinoma
- Recurrent Renal Cell Carcinoma
- Solid Neoplasm
- Stage IV Breast Cancer
- Stage IV Non-Small Cell Lung Cancer
- Stage IV Renal Cell Cancer
- Stage IV Skin Melanoma
- Stage IVA Colorectal Cancer
- Stage IVA Pancreatic Cancer
- Stage IVB Colorectal Cancer
- Stage IVB Pancreatic Cancer
Interventions
- Cyclophosphamide Drug
- Laboratory Biomarker Analysis Other
- Pegfilgrastim Biological
- Pharmacological Study Other
- TLR8 Agonist VTX-2337 Drug
Drug · Other · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 4, 2016
- Primary completion
- Sep 25, 2016
- Completion
- May 31, 2017
- Last update posted
- Sep 4, 2018
2016 – 2017
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic in Arizona | Scottsdale | Arizona | 85259 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02650635, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 4, 2018 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02650635 live on ClinicalTrials.gov.